Long‐term treatment of cancer‐prone germline PTEN mutant mice with low‐dose rapamycin extends lifespan and delays tumour development

Abstract

PTEN is one of the most commonly inactivated tumour suppressor genes in sporadic cancer. Germline heterozygous PTEN gene alterations also underlie PTEN hamartoma tumour syndrome (PHTS), a rare human cancer-predisposition condition. A key feature of systemic PTEN deregulation is the inability to adequately dampen PI3-kinase (PI3K)/mTORC1 signalling. PI3K/mTORC1 pathway inhibitors such as rapamycin are therefore expected to neutralise the impact of PTEN loss, rendering this a more druggable context compared with those of other tumour suppressor pathways such as loss of TP53. However, this has not been explored in cancer prevention in a model of germline cancer predisposition, such as PHTS. Clinical trials of short-term treatment with rapamycin have recently been initiated for PHTS, focusing on cognition and colon polyposis. Here, we administered a low dose of rapamycin from the age of 6 weeks onwards to mice with heterozygous germline Pten loss, a mouse model that recapitulates most characteristics of human PHTS. Rapamycin was well tolerated and led to a highly significant improvement of survival in both male and female mice. This was accompanied by a delay in, but not full blockade of, the development of a range of proliferative lesions, including gastro-intestinal and thyroid tumours and endometrial hyperplasia, with no impact on mammary and prostate tumours, and no effect on brain overgrowth. Our data indicate that rapamycin may have cancer prevention potential in human PHTS. This might also be the case for sporadic cancers in which genetic PI3K pathway activation is an early event in tumour development, such as endometrial cancer and some breast cancers. To the best of our knowledge, this is the first report of a long-term treatment of a germline cancer predisposition model with a PI3K/mTOR pathway inhibitor.

Chemotherapy’s effects on autophagy in the treatment of Hodgkin’s lymphoma: a scoping review

“…This duality of autophagy function in cancer prevention and formation can be illustrated by the findings derived from the study using mTOR inhibitors in cancers. The administration of rapamycin or other mTOR inhibitors was shown to delay cancer formation in cancer-prone mice infected by the Human Papilloma Virus (HPV) [ 80 ] or carrying mutations in Her2/Neu [ 81 , 82 ], p53 [ 83 , 84 ], PTEN [ 85 ], and other types of mutations [ 86 , 87 ]. Additionally, evidence on kidney transplant patients found that using mTOR inhibitors protects de novo cancer formation, preventing up to half of the expected incidence of cancers [ 88 – 91 ].…”

Chemoprevention in hereditary digestive neoplasia: A comprehensive review

“…87 Cowden's syndrome In a PTEN-inactivated mouse model mimicking the Cowden syndrome phenotype, inhibition of the mTOR pathway by sirolimus results in a decrease in the number of digestive polyps 88 and an increase in life span. 89 In a series of 14 adult patients treated with sirolimus 2 mg daily for 2 months assessed endoscopically before and after treatment, regression of colonic polyps was noted in only two patients (14%). 90…”

Cancer prevention with rapamycin

“…In cancer-prone germline PTEN mutant mice, longterm treatment (started at the age of 6 week) with low doses of rapamycin extended lifespan and delayed tumor development [12].…”